RAEB


Also found in: Medical.
AcronymDefinition
RAEBRefractory Anemia with Excess Blast (hematology)
References in periodicals archive ?
Survival of patients with RAEB 1 myelodysplastic syndrome is poor (14-17 months), and even with hematopoietic stem cell transplantation it increases only to 55.6-62.2 months, depending on the initial percentage of bone marrow blast cells.
M, male; F, female; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; ND, not described; IP, interstitial pneumonia.
Distribution of subtypes of MDS by age Subtype No.(%) <19 20-24 25-29 30-34 35-39 40-44 RA 55(37.93) 2 3 4 6 8 10 RAEB 41(28.27) -- 2 2 5 5 8 RAEB-t 30(20.69) -- -- 3 S 3 4 CMMOL 10(6.90) -- -- -- 2 1 1 RARS 9(6.21) -- -- 2 1 1 -- Total 145 2 5 11 19 18 23 % 1.38 3.45 7.59 13.10 12.41 15.86 Subtype 45-49 50-54 55-59 60 RA 4 5 6 7 RAEB 3 4 6 6 RAEB-t 3 4 3 5 CMMOL 3 1 2 -- RARS -- 1 1 3 Total 13 15 18 21 8.96 10.34 12.41 14.48 RA, refractory anaemia; RAEB.
Gender Age MDS type Karyotype 1 Male 48 RA + 8 2 Male 53 RARS -20 3 Female 65 RAEB -8 4 Male 60 RAEB 20q- 5 Female 63 RAEB-T -7 6 Male 45 RA -Y 7 Male 55 RAEB +8 8 Female 40 RAEB-T 20q- 9 Male 42 RARS 5q- MDS: myelodysplastic syndromes; RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; RAEB refractory anemia with excess blasts; RAEB-T: refractory anemia with excess blasts in transformation.
HCV is found with increased risk of haemopoietic malignancies-ALL, RAEB, NHL & AML HBsAg is reported controversially, having no relation with hemopoietic malignancies to increased risk of RAEB,CML with HBsAg Anti-HBcAg with AML(12).
Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.
On the other hand, we obtained promising results in children with various subtypes of MDS (refractory anemia with excess blast (RAEB), RAEB in transformation, juvenile myelomonocytic leukemia (JMML) and CMML) with the addition of HDMP to cytotoxic chemotherapy [66,78,79], with the exception of patients with JMML and monosomy 7.
Patient samples and DNA isolation: Forty one MDS samples including 17 RA (refractory anaemia), 4 RARS (refractory anaemia ringed sideroblast), 9 RAEB (refractory anaemia excess blast), 6 RAEB-t (refractory anaemia excess blast in transformation) and 5 AML secondary to MDS (MDS/AML) according to the French-American-British (FAB) classification were used in the study.
Samples were classified according to the French-American-British system: refractory anemia (RA; n = 13), RA with ringed sideroblasts (BARS; n = 22), RA with excess blasts (RAEB; n = 24), chronic myelomonocytic leukemia (CMML; n = 24), and AML (n = 11), and 32 control samples (biopsies displaying only mild reactive alterations) from the archive of the Institute of Pathology.
However association of HBV with RAEB, CML &AML are reported in very few cases.
Regardless, when mutations occur, they are usually found in the high-risk morphologic subtypes of MDS that are associated with a poor outcome and a propensity to evolve to AML, that is, refractory anemia with excess blasts (RAEB) and refractory anemia with excess blasts in transformation (RAEBT).
According to existing French-American-British (FAB) classification, the case was categorized as--refractory anemia with excess blasts (RAEB) and myelofibrosis.